Acipimox Pharma Grade API is supplied as a white to almost white crystalline powder corresponding to 5-methylpyrazine-2-carboxylic acid 4-oxide, CAS 51037-30-0, molecular formula C₆H₆N₂O₃, and relative molecular mass 154.12 g mol⁻¹. The substance is controlled against the current pharmacopoeial monograph for acipimox, with residual solvents assessed under ICH Q3C and elemental impurities under ICH Q3D. Two release profiles are maintained for the same chemical entity: an oral grade for tablet, capsule, and granule operations, and a low-endotoxin grade intended for use in injectable solution manufacturing. The oral grade is characterised primarily by particle size distribution, powder flow, residual water, and chemical purity; the injectable grade is additionally released against bacterial endotoxin and bioburden controls calculated from the intended parenteral route. The product is not a sterile API; injectable sterility is achieved during finished dosage form manufacture.

Solid-State Characterization and Powder Rheology Are Not Trivial for Low-Dose Tablets

The pyrazine N-oxide structure differs from pyridine-based niacin and influences both pH-dependent solubility and oxidative stability. Release of oral-grade acipimox includes X-ray powder diffraction to confirm that no additional polymorphic reflections appear relative to the reference diffractogram; this is necessary because changes in crystal habit can shift bulk density and blending behaviour. Particle size is measured by laser diffraction per Ph. Eur. 2.9.31. A representative micronized oral grade may carry a D₉₀ specification of ≤75 µm for direct compression, while granulated grades are controlled after sieving at ≤250 µm. Bulk density and tapped density are determined according to Ph. Eur. 2.9.34; powders with a Hausner ratio above 1.35 generally require granulation or glidant addition before tablet compression. Water content is measured by Karl Fischer titration per Ph. Eur. 2.5.12, with a representative oral-grade limit of ≤0.5%.

On pilot-scale direct-compression lines, batch-to-batch variation in particle size distribution can influence blend uniformity and tablet weight control even when assay values meet release limits. Blend uniformity is evaluated per Ph. Eur. 2.9.40; feasibility batches are typically sampled at 10–20 positions across a bin blender with acceptance limits applied to the coefficient of variation. For capsule filling, filled weight may be more sensitive to powder flow than to static blend assay, and colloidal silicon dioxide at 0.25–1.0% w/w is often introduced when the API is cohesive. High-shear wet granulation in a top-drive granulator with impeller speed 120–250 rpm and chopper speed 1800–2400 rpm is used when direct compression fails due to poor flow. Granulation liquid is purified water or a low-viscosity binder solution; wet mass endpoint is controlled by impeller torque or power consumption. Drying in a fluid-bed dryer with inlet air temperature 55–65 °C and exhaust temperature 30–40 °C is then employed to reach a dried granule moisture endpoint of 1.0–2.5%. These ranges are representative and must be confirmed for each formulation because the drying curve depends on binder type and granulate density.

Dissolution testing of immediate-release acipimox tablets is typically performed with apparatus II at 50 rpm in 900 mL of aqueous buffer at 37 °C, but the final method is product-specific and must justify sink conditions. Early development should compare media at pH 1.2, 4.5, and 6.8. If dissolution data show an inflexion at pH 4.5, wet granulation with a hydrophilic binder is preferred over dry blending of micronized API. Granule particle size after dry milling is controlled to a D₅₀ of 80–150 µm for encapsulation and 150–250 µm for tablet compression; these are design targets rather than compendial limits. Dry granulation by roller compaction is used when wet granulation is incompatible with sensitiser or when manufacturing capacity lacks fluid-bed drying. Roller-compacted material has a higher bulk density and lower surface area than wet-granulated material; dissolution can therefore be slightly slower. Ribbon milling screen sizes between 1.0 mm and 1.6 mm are typical starting points.

What Process Controls Distinguish Injectable-Grade Acipimox from Oral Supplies?

The injectable grade is not a terminally sterilised API; sterility is achieved by the dosage-form manufacturer through moist-heat sterilisation or sterilising filtration at 0.22 µm pore size. The API is instead controlled for low bioburden, endotoxin content, and particulate behaviour after dissolution. Endotoxin limits are calculated from the maximum adult parenteral dose using the formula given in Ph. Eur. 5.1.10. A representative release criterion of ≤0.50 EU/mg is applied when the daily parenteral dose is 500 mg; the final limit must be derived from the product’s actual clinical dosing schedule. Filter compatibility is evaluated with polyvinylidene fluoride and polyethersulfone membranes, and the manufacturer should provide a filter validation report for the specific solution pH and concentration.

Because acipimox contains an N-oxide group, storage under reducing conditions and contact with strong reducing agents should be controlled. Forced degradation studies under acidic, alkaline, oxidative, thermal, and photolytic conditions are used to qualify the related-substances HPLC method. Bulk containers should be airtight and protected from light; long-term and accelerated stability data are generated at 25 °C/60% RH and 40 °C/75% RH per ICH Q1A(R2). Manufacturers transferring the oral grade into low-dose combinations should repeat blend uniformity and degradation studies when the API is co-processed with acidic or reducing excipients.

When Terminal Sterilisation or Aseptic Processing Is Selected for the Solution Dosage Form

The low-endotoxin injectable grade supports both aseptic filling and terminal sterilisation routes, but the API’s thermal stability in the final container must be confirmed before selecting moist-heat sterilisation at 121 °C for 15 min. If the solution is heat labile or the container provides insufficient heat transfer, sterilising filtration followed by aseptic fill is used. The API particle size is then less relevant to blend uniformity than to dissolution during compounding; nevertheless, oversized particles can delay solubility and overload pre-filtration membranes. Dissolved oxygen and headspace inerting may be required to limit oxidative degradation. The formulation should be challenged with spiked peroxide and light stress to verify the related-substances method capacity. For injectable solution manufacture, the API is dissolved in water for injection with pH adjustment using a pharmacopoeial buffer or sodium hydroxide. The target solution pH is usually maintained between 5.0 and 7.0 to balance solubility and stability; nitrogen blanketing may be applied. Process validation should include pre-use and post-use filter integrity testing according to the filter manufacturer’s validated protocol.

Comparative Position Among Niacin Derivatives and Pyridine Carboxamides

Acipimox differs from niacin in its pyrazine N-oxide heterocycle and 5-methyl substituent. This structural change modifies the interaction with hydroxycarboxylic acid receptors and is associated with a lower reported vasodilatory flushing response than immediate-release niacin; comparative lipid-modifying efficacy should be assessed from controlled clinical data rather than receptor binding alone. Unlike nicotinamide, acipimox retains the carboxylic acid function required for lipolysis inhibition in adipose tissue. Nicotinamide primarily serves as an NAD precursor and does not share the same primary receptor-mediated free fatty acid–lowering profile. In formulation terms, the differences appear as lower dose strength per unit, higher aqueous solubility need, and distinct related-substances profiles. Table 2 summarises key structural and use differences.

Bulk storage of oral-grade acipimox in fibre drums with double polyethylene liners is adequate for dry zones when warehouse temperature does not exceed 25 °C and relative humidity remains below 60%. For zones with relative humidity above 60%, the manufacturer’s stability data should be reviewed before opening the drum; repeated opening can increase water uptake in hygroscopic formulations even if acipimox itself is not highly hygroscopic. Cleaning validation for multi-product facilities should account for the N-oxide-containing molecule’s potential to form degradation products under oxidative stress. Swab and rinse samples are analysed by the same HPLC related-substances method used for release. Equipment contact surfaces should be passivated stainless steel; contact with carbon steel may require additional cleaning verification. Published data for acipimox-specific powder flow at commercial scale is limited; technical transfer packages should therefore include manufacturer lots rather than relying solely on public compendial data.